News articles about Viewray (NASDAQ:VRAY) have been trending somewhat negative this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Viewray earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave press coverage about the company an impact score of 47.0446052519038 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:
- Should You Buy ViewRay Inc (NASDAQ:VRAY) At US$07.07? (finance.yahoo.com)
- Stock’s Earnings Per Share (EPS) – Brief Analysis – ViewRay Inc (NASDAQ: VRAY) (stocksmarketcap.com)
- Intraday Trade Secrets – ViewRay Inc (NASDAQ: VRAY) (stockspen.com)
- Running Mover to Focus- ViewRay, Inc. (VRAY) (nasdaqfortune.com)
- Is this stock is Attractive? ViewRay, Inc. (VRAY) (connectinginvestor.com)
Shares of NASDAQ:VRAY traded down $0.05 during midday trading on Thursday, reaching $7.05. The company’s stock had a trading volume of 495,281 shares, compared to its average volume of 672,996. The company has a market capitalization of $529.47 million, a PE ratio of -6.78 and a beta of 0.56. The company has a debt-to-equity ratio of 0.77, a current ratio of 3.79 and a quick ratio of 3.04. Viewray has a 12-month low of $4.40 and a 12-month high of $10.64.
Viewray (NASDAQ:VRAY) last released its earnings results on Thursday, May 10th. The company reported ($0.11) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.20) by $0.09. The firm had revenue of $26.19 million for the quarter, compared to the consensus estimate of $15.50 million. Viewray had a negative net margin of 83.09% and a negative return on equity of 1,375.57%. The company’s revenue was up 2029.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.54) EPS. equities analysts anticipate that Viewray will post -0.65 EPS for the current fiscal year.
A number of research analysts have issued reports on the stock. BidaskClub downgraded shares of Viewray from a “sell” rating to a “strong sell” rating in a research report on Thursday, May 17th. Cantor Fitzgerald reissued a “buy” rating and set a $13.00 price objective on shares of Viewray in a research report on Friday, May 11th. ValuEngine raised shares of Viewray from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Finally, Mizuho reissued a “buy” rating and set a $12.00 price objective on shares of Viewray in a research report on Thursday, April 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. Viewray has an average rating of “Buy” and an average price target of $11.90.
Viewray Company Profile
ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.
Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.